News
BGNE
156.39
+0.84%
1.31
4 Analysts Assess BeiGene: What You Need To Know
BeiGene Ltd is a commercial-stage biotechnology company developing drugs for the treatment of cancer. 4 analysts have published ratings on BeiGene in the last three months. The company has an average 12-month price target of $219.25. BeiGene has a positive revenue growth rate of 66.91% over the past year.
Benzinga · 1d ago
BeiGene Is Maintained at Market Perform by Bernstein
Dow Jones · 2d ago
BeiGene Price Target Cut to $161.00/Share From $196.00 by Bernstein
Dow Jones · 2d ago
Bernstein Maintains Market Perform on BeiGene, Lowers Price Target to $161
Benzinga · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
TipRanks · 2d ago
Beigene Ltd: Report of proposed sale of securities
Press release · 2d ago
Sum Up The Parts: QQQJ Could Be Worth $32
NASDAQ · 3d ago
Weekly Report: what happened at BGNE last week (0318-0322)?
Weekly Report · 4d ago
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Novo Nordisk announced plans to invest $556 million to expand its Tianjin production facility. BeiGene was approved to market a new drug in the US.
Seeking Alpha · 4d ago
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Shares of Lululemon Athletica Inc. Fell sharply in today’s pre-market trading after releasing fourth-quarter results. The company posted better-than-expected results but issued a weak forecast for the first quarter. U.S. Stock futures were higher this morning, with the Dow futures gaining 0.1%.
Benzinga · 03/22 09:40
BeiGene Announces Executive Team Reshuffle and Director Pay Revision
TipRanks · 03/20 20:22
Weekly Report: what happened at BGNE last week (0311-0315)?
Weekly Report · 03/18 09:05
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
FDA approves BeiGene's cancer drug Tevimbra as monotherapy for adult patients. The drug will be available in the U.S. In the second half of 2024. The approval represents the first indication in the US for the drug. BeiGene will regain rights to the drug from Novartis AG in 2023.
Benzinga · 03/15 17:01
BeiGene: Hold Recommendation Amidst Mixed Financial Indicators and Robust Drug Pipeline Growth
TipRanks · 03/15 12:25
BRIEF-Beigene Receives FDA Approval For Tevimbra
Reuters · 03/15 00:28
BeiGene gets FDA approval for esophageal cancer drug Tevimbra
BeiGene gets FDA approval for esophageal cancer drug Tevimbra. The drug was approved for the treatment of advanced or metastatic esophagesal squamous cell carcinoma. The company plans to launch the drug in the US in the second half of the year.
Seeking Alpha · 03/14 22:46
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
FDA approves Tevimbra to treat certain adult patients with unresectable or metastatic esophageal squamous cell carcinoma. The treatment will be available in the U.S. In the second half of this year. BeiGene says this is the first U.s. Indication for the drug.
Dow Jones · 03/14 21:07
BeiGene Secures FDA Approval For TEVIMBRA For Treatment Of Advanced Or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
TEVIMBRA will be available in the U.S. In the second half of 2024. The FDA is also reviewing tislelizumab as a first-line treatment for patients with ESCC and gastric cancer. The target action dates are July and December 2024.
Benzinga · 03/14 20:29
US FDA approves BeiGene's esophageal cancer therapy
Reuters · 03/14 18:14
FDA Approves Beigene's Tevimbra As Of March 13, 2024
Benzinga · 03/14 18:13
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.